Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report.

ABSTRACT:

Background

Lung cancer is a malignant tumor with high morbidity and mortality, and its incidence continues to increase. With the emergence of new drugs and treatment modalities, the prognosis of lung cancer patients has improved to some extent. However, the prognosis of initially unresectable, locally advanced lung cancer with immunotherapy combined with chemotherapy remains uncertain.

Case description

We report a case of a 57-year-old man diagnosed with stage IIIB la with negative targeted therapy-related gene mutation and a 2% programmed death 1/programmed cell death-ligand 1 (PD-1/PD-L1) expression level, who underwent transformation treatment with pembrolizumab after multidisciplinary consultation. Lung images indicated partial response after 4 cycles. However, preoperat

SUBMITTER: Zhang S 

PROVIDER: S-EPMC9577729 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature